Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
The human immunodeficiency virus type 1 (HIV-1) resistance profile, K65R, K70E and M184V, on reverse transcriptase gene was associated with the virologic rebound consecutively to the switch of lopinavir/r to tenofovir DF in a stable regimen with nucleoside backbone of abacavir, lamivudine and didanosine. The high selective pressure on the same resistance pathway was probably associated with the loss of antiviral potency, even in well-controlled patient.
Delaugerre
Constance
C
Department of Virology, Necker-Enfants Malades Hospital, 149 rue de Sèvres, 75015 Paris, France. constance.delaugerre@nck.ap-hop-paris.fr
Roudiere
Laurent
L
Peytavin
Gilles
G
Rouzioux
Christine
C
Viard
Jean-Paul
JP
Chaix
Marie-Laure
ML
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D016049:Didanosine / Q000627:therapeutic use; D015224:Dideoxynucleosides / Q000627:therapeutic use; D024882:Drug Resistance, Viral / Q000235:genetics; D005260:Female; D005681:Gabon; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D061466:Lopinavir; D008826:Microbial Sensitivity Tests; D009154:Mutation; D063065:Organophosphonates / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000627:therapeutic use; D000068698:Tenofovir; D019562:Viral Load; D000099227:Abacavir
D000225:Adenine; D019380:Anti-HIV Agents; D016049:Didanosine; D015224:Dideoxynucleosides; D054303:HIV Reverse Transcriptase; D019259:Lamivudine; D061466:Lopinavir; D063065:Organophosphonates; D011744:Pyrimidinones; D000068698:Tenofovir; D000099227:Abacavir